News | Iris Pharma and PMI announce strategic alliance

Iris Pharma and Promedica International announce strategic alliance for expansion of ophthalmology clinical research 

Nice, France – April 27, 2007 - Iris Pharma, a global development service provider specializing in ophthalmology, announced today the establishment of a new strategic alliance with Promedica International (PMI), a USA-based Contract Research Organization (CRO). PMI is an ISO 9001:2000 certified CRO with extensive experience in ophthalmology clinical research.
The company services include clinical study management and monitoring, data management and statistics, medical writing, GCP compliance, and strategic consulting for the medical device, biotech, and pharmaceutical industry.
Iris Pharma decided to formalize the alliance with PMI in order to strengthen its presence in the USA through a company with deep cultural similarities in terms of client orientation and service.
“The PMI-Iris Pharma alliance creates an excellent value for our clients”, stated Pierre-Paul Elena, PhD, founder of Iris Pharma. “Now our clients will have the opportunity to perform study activities in Europe and North America using common project and data management resources and a single set of standard operating procedures.”
“The PMI-Iris Pharma alliance expands both firms’ capabilities. Our combined experience and service provider relationships in this field facilitate comprehensive, efficient clinical project plans and implementation in both North America and Europe. Over the years we have reviewed various alliance opportunities – we find Iris Pharma’s capabilities and culture to be a good match with PMI’s focus on people, processes and performance”, said Ellen Palo, PMI founder.
Yann Quentric, Director of Business Development for the Clinical Department of Iris Pharma said, “This alliance between Iris Pharma and PMI, two well-established CROs in Europe and North America, is the opportunity to offer our customers a « onestop shopping » solution and to confidently provide them with a high quality global service. As a result we will be able to increase our responsiveness, our flexibility, and our cost effectiveness.” Both companies will have exhibit booths at the Association for Research in Vision and Ophthalmology (ARVO), which is May 6 – 10, 2007 in Fort Lauderdale, FL. Iris Pharma will also have exhibit booth at the BIO International Convention (French Pavilion), which is May 6 – 9, 2007 in Boston, MA.

About Iris Pharma:
Iris Pharma is an independant CRO headquartered in Nice, France, dedicated to pre-clinical and clinical research in ophthalmology. Created in 1989, it provides drug development services to Research Institutes, Pharmaceutical or Biotechnology Industries. It today groups four areas of complementary activities: bioanalysis and formulation, pre-clinical studies and services, clinical trials, and strategic consulting. Iris Pharma has been selected by the European Vision Institute Clinical Trials Sites of Excellence, a network of European ophthalmic clinical research sites, as an independent expert for optimizing their network consolidation through consulting, site audits, and certification.

For more information, please visit

About Promedica International:
Promedica International (PMI) is a privately held corporation with headquarters located in Costa Mesa, California. Founded in 1985, the company provides specialized clinical research services to the medical device, biotech and pharmaceutical industries. ISO 9001:2000 certified and servicing a range of medical specialties and therapeutic areas, the company has extensive experience in clinical study services for ophthalmology projects, and has provided support for studies evaluating treatment for an extensive range of anterior and posterior segment disorders.

For more information, please visit